Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
Date:5/4/2009

-Preliminary Data from This Trial to be Presented at ASCO-

-First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment-

TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment in its Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. The planned 46 patients have been enrolled and are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label Phase II study is to assess the overall response rate to bavituximab and docetaxel. The company also announced that preliminary data from this trial has been accepted for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

"Completion of patient enrollment in this Phase II study in advanced breast cancer patients represents a milestone for Peregrine's bavituximab cancer program, as this is the first of our three ongoing Phase II cancer trials to complete patient enrollment," said Steven W. King, president and CEO of Peregrine. "We will continue to assess patients in this study over the coming months and look forward to reporting updated preliminary results from the trial at the upcoming ASCO Annual Meeting."

In this trial's Simon two-stage design, 15 patients with advanced breast cancer were enrolled in the trial's first cohort. Ten of the 14 evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria. These results compare favorably with historical response rates for docetaxel as solo therapy in advanced breast cancer patients and exceeded the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

Secondary obj
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
2. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
3. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
4. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
11. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "Market Assessment of Respiratory ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... respiratory imaging diagnostics market in the ... . The service provides detailed analysis of ...
(Date:5/21/2015)... CITY, Calif. , May 21, 2015  Cardica, Inc. ... 2015, new employee Greg Watson , the company,s vice ... shares of the company,s common stock, at a per share ... 20, 2015. The stock option was granted pursuant to Cardica, ... of directors in May 2015 under Rule 5653(c)(4) of the ...
(Date:5/21/2015)... , 21. Mai 2015 /PRNewswire/ ... DPRX ), ein Unternehmen für Arzneimittel ... die Entwicklung und Vermarktung von Locilex® ... kündigte heute eine wissenschaftliche Posterpräsentation an, ... des Unternehmens vorstellt, OneStep-1 und OneStep-2, ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2Cardica Announces New Employment Inducement Grant 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ; ... and nine months ended March 31, 2011 (Third Quarter of ... Began initial production of the Unifill® ready-to-fill (prefilled) syringe ... commence in July 2011 Initiated scheduled business realignment ...
... 2011 Massachusetts providers of home medical equipment and ... Congress to repeal the flawed, controversial Medicare "competitive" bidding ... "Massachusetts, medical suppliers need H.R. 1041. If ... businesses and hurt the state,s more than one million ...
Cached Medicine Technology:Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 2Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 3Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 4Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 5Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 6Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 7Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 8Unilife Announces Financial Results for the Third Quarter of Fiscal 2011 9Massachusetts Home Medical Equipment Providers Back Federal Legislation to Repeal Controversial Medicare Bidding Program 2Massachusetts Home Medical Equipment Providers Back Federal Legislation to Repeal Controversial Medicare Bidding Program 3Massachusetts Home Medical Equipment Providers Back Federal Legislation to Repeal Controversial Medicare Bidding Program 4
(Date:5/22/2015)... Halifax, NS (PRWEB) May 22, 2015 ... into a sale agreement with US-based health brand Nature’s ... Ascenta Skin brand. Retention of Ascenta Skin is an ... St-Onge is excited about this opportunity to further develop ... industry. , Ascenta Skin is a breakthrough, anti-aging ...
(Date:5/22/2015)... “It’s like learning an new language,” ... President of Clinical Operations/Education and Training at Harmony ... how care is coded and reimbursed.” , Harmony ... reimbursement, operations and compliance consulting, as well as ... a new series of day-long seminars on the ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning ... some tips to help promote safe travel. , According to ... traffic fatalities this Memorial Day weekend. Amica is sharing the ... Association: , , Always wear a ... seatbelt, whether they’re driving or riding along as a passenger. ...
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
(Date:5/22/2015)... Medivo, Inc., a leader in lab data analytics, ... in ‘Baby Boomers’ Screened for HCV Following the 2012 CDC ... at Digestive Disease Week, May 16-19, 2015. , The ... members Carol Smyth, MB; Jason Bhan, MD; Tatiana Sorokina, MSc; ... Nancy Reau, MD from the University of Chicago, Chicago, IL. ...
Breaking Medicine News(10 mins):Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2
... SAN FRANCISCO, Nov. 26 While most businesses ... http://www.justanswer.com/ ) will,be in full effect as Doctors, ... answers to those with questions at all hours. ... than 70 categories, the,JustAnswer platform makes it simple ...
... ORLANDO, Fla., Nov. 26 Valensa International ... Parry (India) Ltd., Chennai,India), as part of ... joined forces to,usher in the next generation ... the condition-specific dietary supplement,functional food and fortified ...
... experience working with NHS customers , , ... (IAM) specialist for the healthcare sector, has today announced the appointment ... the company,s sales and channel operations in the UK. , ... IT experience to Sentillion, having spent over 20 years working for ...
... of two roosters along with the keys to a new health clinic ... workers from 10 villages and has been handed over to the Ministry ... of the residents of Tenegar and surrounding villages for many years to ... ...
... men develop enlarged, inflamed, or life threatening cancerous prostate glands. Men ... prostate” to reduce suffering, as recommended by hundreds of medical doctors ... ... 2008 -- Most men are expected to have some kind of ...
... 26 Johnson & Johnson Pharmaceutical Research & Development, ... Response letter from the U.S. Food and Drug Administration ... for the treatment of complicated skin and skin structure ... , The FDA has indicated that ...
Cached Medicine News:Health News:Experts on JustAnswer(R) Projected to Help Thousands During the Thanksgiving Holiday 2Health News:Experts on JustAnswer(R) Projected to Help Thousands During the Thanksgiving Holiday 3Health News:Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace 2Health News:Sentillion Appoints New UK Sales Manager 2Health News:Tenegar Town Celebrates Dedication Of New Clinic As Beacon Of Hope 2Health News:Tenegar Town Celebrates Dedication Of New Clinic As Beacon Of Hope 3Health News:ProstateCradle.com Launches the First “External Prostate Massager” by Enviromax, a Sensational Way to Help Millions of Men Have Healthier Prostate Glands 2Health News:FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections 2Health News:FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: